HK1091727A1 - Nasal pharmaceutical formulations and methods of using the same - Google Patents

Nasal pharmaceutical formulations and methods of using the same

Info

Publication number
HK1091727A1
HK1091727A1 HK06112257.7A HK06112257A HK1091727A1 HK 1091727 A1 HK1091727 A1 HK 1091727A1 HK 06112257 A HK06112257 A HK 06112257A HK 1091727 A1 HK1091727 A1 HK 1091727A1
Authority
HK
Hong Kong
Prior art keywords
methods
same
pharmaceutical formulations
nasal pharmaceutical
nasal
Prior art date
Application number
HK06112257.7A
Other languages
English (en)
Inventor
Imtiaz Chaudry
Original Assignee
Dey Pharma L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/003314 external-priority patent/WO2004091574A1/en
Application filed by Dey Pharma L P filed Critical Dey Pharma L P
Publication of HK1091727A1 publication Critical patent/HK1091727A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029—Radiation
    • A61L2/0035—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK06112257.7A 2003-04-16 2006-11-08 Nasal pharmaceutical formulations and methods of using the same HK1091727A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/414,756 US7811606B2 (en) 2003-04-16 2003-04-16 Nasal pharmaceutical formulations and methods of using the same
PCT/EP2004/003314 WO2004091574A1 (en) 2003-04-16 2004-03-29 Nasal pharmaceutical formulations and methods of using the same

Publications (1)

Publication Number Publication Date
HK1091727A1 true HK1091727A1 (en) 2007-01-26

Family

ID=33158765

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06112257.7A HK1091727A1 (en) 2003-04-16 2006-11-08 Nasal pharmaceutical formulations and methods of using the same

Country Status (14)

Country Link
US (3) US7811606B2 (es)
EP (1) EP1613281B1 (es)
JP (1) JP5403868B2 (es)
KR (1) KR101312331B1 (es)
CN (1) CN1805729B (es)
AU (1) AU2004229148B8 (es)
BR (1) BRPI0409434A (es)
CA (1) CA2522291C (es)
ES (1) ES2609910T3 (es)
HK (1) HK1091727A1 (es)
MX (1) MXPA05011105A (es)
RU (1) RU2373925C2 (es)
WO (1) WO2004091575A1 (es)
ZA (1) ZA200509238B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544192B2 (en) * 2003-03-14 2009-06-09 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
KR100675379B1 (ko) * 2005-01-25 2007-01-29 삼성전자주식회사 프린팅 시스템 및 프린팅 방법
CA2603081C (en) * 2005-04-04 2013-09-03 Sinexus, Inc. Device and methods for treating paranasal sinus conditions
US8535707B2 (en) * 2006-07-10 2013-09-17 Intersect Ent, Inc. Devices and methods for delivering active agents to the osteomeatal complex
DK2231065T3 (da) 2007-12-18 2021-02-01 Intersect Ent Inc Selvekspanderende anordninger
CA2732355A1 (en) 2008-08-01 2010-02-04 Intersect Ent, Inc. Methods and devices for crimping self-expanding devices
US7863074B2 (en) * 2008-09-30 2011-01-04 Stion Corporation Patterning electrode materials free from berm structures for thin film photovoltaic cells
EP3103502A1 (en) * 2009-05-15 2016-12-14 Intersect ENT, Inc. Expandable devices and methods therefor
ES2612257T3 (es) * 2011-05-03 2017-05-16 Chiesi Farmaceutici S.P.A. Formulación de suspensión mejorada de dipropionato de beclometasona para administración mediante inhalación
BR112013027390A2 (pt) * 2011-05-04 2017-01-17 Chiesi Farma Spa formulação farmacêutica
EP3636227B1 (en) 2013-03-14 2024-08-28 Intersect ENT, Inc. Systems and devices for treating a sinus condition
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN113679931A (zh) 2015-01-22 2021-11-23 因特尔赛克特耳鼻喉公司 药物涂覆的气囊
CN104940994B (zh) * 2015-07-14 2017-09-19 江苏威克斯医疗科技有限公司 一种人造鼻粘膜及其用途
CN107320449B (zh) * 2017-08-07 2020-09-15 武汉武药科技有限公司 丙酸氟替卡松鼻喷雾剂及其制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
DE3887591T2 (de) 1987-07-07 1994-05-19 Beecham Group Plc Pinacidil zur Behandlung von pulmonaler Hypertonie oder Rechtsversagen.
AU610175B2 (en) 1988-05-25 1991-05-16 Biogal Gyogyszergyar Pharmaceutical composition comprising a compound containing sulfhydryl group(s) for the treatment of otitis
JPH03165833A (ja) * 1989-02-28 1991-07-17 Isamu Horikoshi 新規懸濁化方法及びこの方法によって得られる組成物
CA2010894A1 (en) 1989-02-28 1990-08-31 Isamu Horikoshi Method of forming a suspension and composition formed by said method
SE9000207L (sv) 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
CA2091360C (en) 1990-09-10 1997-04-08 Pui-Ho Yuen Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5177447A (en) * 1990-11-06 1993-01-05 Bear Automotive Service Equipment Company Automated breakout box for automotive testing
US5174475A (en) 1991-03-26 1992-12-29 Glaxo Inc. Sequential dosing of antifungal and antiinflammatory compositions
US5593688A (en) 1993-06-25 1997-01-14 Nexstar Pharmaceuticals, Inc. Liposomal targeting of ischemic tissue
JPH0753358A (ja) 1993-08-17 1995-02-28 Teijin Ltd 吸入剤
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US6113894A (en) 1995-01-23 2000-09-05 Smith; S. Gregory Ophthalmic compositions and process of using
IT1275955B1 (it) 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
AU7106996A (en) 1995-09-07 1997-03-27 Fuisz Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
TW416953B (en) 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
FR2756739B1 (fr) 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
DE69804998T2 (de) 1997-10-09 2002-12-12 Schering Corp., Kenilworth Mometasonfuroat-suspensionen zum zerstäuben
EE200000253A (et) 1997-10-22 2001-06-15 Ponikau Jens Seentevastase toimeaine kasutamine ravimite valmistamiseks, mis on ette nähtud mitteinvasiivsetest seenorganismidest tingitud haiguste raviks või vältimiseks
JP3386349B2 (ja) 1997-10-30 2003-03-17 帝人株式会社 水性懸濁医薬品組成物
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6423423B2 (en) 1998-05-06 2002-07-23 Calsonic Kansei Corporation Formed strip and roll forming
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
CA2341732C (en) 1998-08-26 2008-08-19 Teijin Limited Powder composition for nasal administration
IT1303692B1 (it) 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
US20040141925A1 (en) 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
WO2000074699A1 (en) 1999-06-03 2000-12-14 Johnson & Johnson Consumer France Sas Extracts of feverfew (tanacetum parthenium) against inflammatory disorders
JP2001002589A (ja) * 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
US20020061281A1 (en) 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU6076200A (en) 1999-07-08 2001-01-30 Johnson & Johnson Consumer Companies, Inc. Exothermic bandage
GB9918559D0 (en) * 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
AU6852900A (en) 1999-08-20 2001-03-19 Norton Healthcare Ltd Method to produce powders for pulmonary or nasal administration
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
FI20002217A (fi) 1999-12-30 2001-07-01 Orion Yhtymae Oyj Inhalaatiopartikkelit
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
GB0016040D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DK2153819T3 (da) 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
US6608054B2 (en) 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20020090388A1 (en) 2000-12-01 2002-07-11 Humes H. David Intravascular drug delivery device and use therefor
DE10060890C2 (de) 2000-12-07 2003-04-03 Meta Motoren Energietech Vorrichtung zum Umschalten des Betriebs eines Ladungswechselventils einer Brennkraftmaschine
MXPA03006958A (es) * 2001-02-05 2003-11-18 Upjohn Co Composicion para administracion rectal de farmaco antibacterial de oxazolidinona.
GB0105560D0 (en) 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
EP1423107B1 (en) 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
AU2002355419A1 (en) 2001-08-06 2003-02-24 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
FR2831446B1 (fr) 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same

Also Published As

Publication number Publication date
CA2522291A1 (en) 2004-10-28
AU2004229148B8 (en) 2010-12-02
RU2373925C2 (ru) 2009-11-27
BRPI0409434A (pt) 2006-04-18
JP2006523629A (ja) 2006-10-19
JP5403868B2 (ja) 2014-01-29
CN1805729B (zh) 2010-09-22
WO2004091575A1 (en) 2004-10-28
CA2522291C (en) 2011-12-06
ZA200509238B (en) 2007-04-25
EP1613281B1 (en) 2016-10-05
KR20060003009A (ko) 2006-01-09
RU2005135332A (ru) 2006-08-10
US8158154B2 (en) 2012-04-17
EP1613281A1 (en) 2006-01-11
US20080058295A1 (en) 2008-03-06
US7811606B2 (en) 2010-10-12
ES2609910T3 (es) 2017-04-25
MXPA05011105A (es) 2006-05-19
KR101312331B1 (ko) 2013-09-27
AU2004229148B2 (en) 2010-11-25
CN1805729A (zh) 2006-07-19
US20060039871A1 (en) 2006-02-23
US20040208831A1 (en) 2004-10-21
AU2004229148A1 (en) 2004-10-28
US7972627B2 (en) 2011-07-05

Similar Documents

Publication Publication Date Title
HK1164133A1 (en) Nasal pharmaceutical formulations and methods of using the same
HK1091727A1 (en) Nasal pharmaceutical formulations and methods of using the same
HK1084883A1 (en) 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
GB0210397D0 (en) Pharmaceutical formulations
HK1078086A1 (zh) 雜芳族五環化合物及其醫藥用途
IL170758A0 (en) 7-amino-isoindolyl compounds and their pharmaceutical uses
EP1479666A4 (en) ESTER CONNECTION AND THEIR MEDICAL USE
IL176384A (en) Pyrrolidinochlorinated basazole and pharmacy preparations containing them
GB0302671D0 (en) Pharmaceutical formulations
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
EP1646355A4 (en) PHARMACEUTICAL FORMULATIONS
IL163868A (en) Hemiasterlin derivatives and pharmaceutical compositions comprising them
GB2392093B (en) Pharmaceutical formulations
IL162937A0 (en) Pravastatin pharmaceutical formulations and methods of their use
GB0202900D0 (en) Novel formulations of drugs
GB0302672D0 (en) Pharmaceutical formulations
IL175746A0 (en) Oral formulations of desoxypeganine and uses thereof
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
IL149377A0 (en) Pharmaceutical formulation comprising melatonin
EP1622623A4 (en) METHOD FOR THE ADMINISTRATION OF ESTROGENIC AND TESTED
IL172096A0 (en) Pharmaceutical formulations comprising amoxicillin and clavulanate
GB0317877D0 (en) Pharmaceutical combinations and formulations with improved stability

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240328